Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about a real-world study that showed positive results when iStent infinite was used in patients with both controlled and uncontrolled intraocular pressure.
Arkadiy Yadgarov, MD:
Hello, my name is Arkadiy Yadgarov, MD. I’m a glaucoma specialist in private practice at Omni Eye in Atlanta, Georgia.
I presented a paper on the results of iStent Infinite in a real-world trial, looking at effectiveness and safety at 12 months. Essentially, the purpose of the study was to corroborate what has already been published in a pivotal trial for the iStent infinite, in which patients had the iStent infinite performed for refractory glaucoma cases. I wanted to see how well that study and the device fit into the real-world practice in which patients come in with either uncontrolled pressures or controlled pressures but are not tolerating their medication.
What the study showed quite profoundly was that the iStent infinite platform is efficacious and safe. We saw a reduction that was statistically significant in both the IOP as well as the medication.
There were 2 cohorts that we looked at, one in which medication use was reduced and pressures remained the same. That cohort was really looking for medication reduction. Then we had another cohort in which medication reduction was not the goal. It was simply pressure reduction, and in that cohort, similarly, we saw that IOP was reduced significantly, whereas medication reduction was moderately reduced.
The conclusions that I came from this study was that the iStent infinite is a fantastic tool for surgeons looking to increase their interventional glaucoma utilization in their practices. Specifically, the patients that they should consider the iStent infinite would be either patients who are controlled with IOP and on medication, but are seeking to reduce their medication burden, and alternatively, iStent infinite would be a very good role in patients who have uncontrolled pressures despite medications and need further IOP reduction.
Related Content
